Moreover, the most recent data showed that PEComa patients harboring TSC2 mutations and treated with mTOR inhibitors have a better ORR and PFS as compared to those with TSC1 mutations. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.